Clinical outcomes of tuberculosis in renal transplant recipients

Yonsei Medical Journal

Volumn 45, Issue 5, 2004, Pages 865-872

  Park, Yoon Soo ^a   Choi, Jun Yong ^a   Cho, Cheong Ho ^a   Chang, Kyung Hee ^a   Song, Young Goo ^a   Kim, Yu Seun ^a   Kim, Jun Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Drug interaction; Renal transplantation; Rifampin; Treatment duration; Tuberculosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETHAMBUTOL; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; GRAFT SURVIVAL; HUMAN; INTESTINE TUBERCULOSIS; KIDNEY TRANSPLANTATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT MONITORING; POSTOPERATIVE PERIOD; RECIPIENT; RECURRENT DISEASE; SIDE EFFECT; TUBERCULOSIS; TUBERCULOUS PLEURISY;

EID: 9144271755     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.5.865     Document Type: Article

References (20)

1. Tuberculosis. Available at: http://www.who.int. Accessed 11 December 2003.
2. American thoracic society/Centers for disease control and prevention/Infectious diseases society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
3. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. Chem Biol Interact 1997;107:17-30.
4. Vandevelde C, Chang A, Andrews D, Riggs W, Jewesson P. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1991;11:88-9.
5. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
6. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983;286:923-5.
7. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2003. Geneva, Switzerland: WHO/CDS/TB/; 2003. p.316.
8. Park JS, Kim MS, Lee JH, Chang J, Kim SK, Jeon KO, et al. Mycobacterial infection after kidney transplantation; single center experience. J Korean Soc Transplant 2001;15:39-46.
9. Drug susceptibility. Available at: http://www.knta.or.kr. Accessed 11 December 2003.
10. Ozbay B, Uzun K. Extrapulmonary tuberculosis in high prevalence of tuberculosis and low prevalence of HIV. Clin Chest Med 2002;23:351-4.
11. Yoon HJ, Song YG, Park WI, Choi JP, Chang KH, Kim JM. Clinical manifestations and diagnosis of extra-pulmonary tuberculosis. Yonsei Med J 2004;45:453-61.
12. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipient: report of five cases and review of the literature. Rev Infect Dis 1983;5: 216-26.
13. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver and heart transplant recipients in Spain. Transplantation 1997;15: 1278-86.
14. Queipo JA, Broseta E, Santos M, Sanchez-Plumed J, Budia A, Jimenez-Cruz F. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect 2003;9:518-25.
15. Qunibi WY, al-Sibai MB, Taher S, Harder EJ, De Vol E, al-Furayh O, et al. Mycobacterial infection after renal transplantation - report of 14 cases and review of the literature. Q J Med 1990;77:1039-60.
16. Hall CM, Willcox PA, Swanepoel CR, Kahn D, VanZyl-Smit R. Mycobacterial infection in renal transplant recipients. Chest 1994;106:435-9.
17. Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A. Tuberculosis and renal transplantation observations from and endemic area of tuberculosis. Postgrad Med J 1986;62:359-62.
18. Naqvi SA, Hussain M, Askari H, Hashmi A, Hussain Z, Hussain I, et al. Is there a place for prophylaxis against tuberculosis following renal transplantation? Transplant Proc 1992;24:1912.
19. Wallace RJ. Antimycobacterial agents. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p.436-48.
20. East and Central African/British Medical Research Council fifth collaborative study: Controlled clinical trial of 4 short-course regiments of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986;67:5-15.